secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcellx, Inc. (ACLX)
CIK:        0001786205
Form:       8-K
Filed at:   2026-02-23T23:59:59+00:00
Accession:  0001193125-26-063955
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.95
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gilead to acquire Arcellx for $115/share plus $5 CVR; implied equity value $7.8B
--------------------------------------------------------------------------------

- Per-share consideration: $115 cash at closing + one CVR worth up to $5 contingent on anito-cel cumulative sales exceeding $6B by Dec 31, 2029.
- Gilead gains full control of anito-cel, a BCMA-directed CAR T-cell therapy currently under FDA review with a PDUFA date of Dec 23, 2026.
- Support stockholders (entities affiliated with NEA, SR One, directors, officers) holding ~10.3% of shares have agreed to tender in the offer.
- Transaction is structured as a tender offer followed by a Section 251(h) merger; Arcellx may pay a $260M termination fee under specified circumstances.
- Arcellx will conduct business in ordinary course and is subject to a no-shop restriction prior to the Offer Acceptance Time.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1786205/000119312526063955/0001193125-26-063955-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1786205/000119312526063955/d112937d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-063955

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer